Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
325.9 DKK | +0.03% | +1.24% | +10.00% |
May. 06 | DEMANT : Q1 sales miss; organic growth guidance unchanged | |
May. 06 | Transcript : Demant A/S, Q1 2024 Interim Management Statement Call, May 06, 2024 |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- With a 2024 P/E ratio at 23.3 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's enterprise value to sales, at 3.63 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.00% | 10.33B | B- | ||
-9.11% | 21.66B | B | ||
+7.87% | 19.64B | A | ||
+13.47% | 14.53B | B | ||
-12.55% | 2.19B | - | ||
+9.29% | 1.85B | B+ | ||
+33.42% | 1.64B | D- | ||
+22.33% | 649M | - | ||
0.00% | 397M | - | - | |
+72.84% | 200M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DEMANT Stock
- Ratings Demant A/S